Therapeutic effects of neuroactive drugs on hypothalamo-pituitary in man.

[1]  G. Besser,et al.  MEGAVOLTAGE PITUITARY IRRADIATION IN THE MANAGEMENT OF CUSHING'S DISEASE AND NELSON'S SYNDROME: LONG‐TERM FOLLOW‐UP , 1989, Clinical endocrinology.

[2]  K. Alberti,et al.  METABOLIC AND HORMONAL RESPONSES TO EXOGENOUS HYPERTHERMIA IN MAN , 1989, Clinical endocrinology.

[3]  A. Grossman,et al.  THE PITUITARY‐ADRENAL RESPONSE TO CRF‐41 IS UNALTERED BY INTRAVENOUS SOMATOSTATIN IN NORMAL SUBJECTS , 1989, Clinical endocrinology.

[4]  E. Oldfield,et al.  The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease. , 1989, The Journal of clinical endocrinology and metabolism.

[5]  A. Grossman,et al.  Stimulation of Alpha‐Adrenoceptors Facilitates the Release of Growth Hormone‐Releasing Hormone from Rat Hypothalamus in vitro , 1989, Journal of neuroendocrinology.

[6]  A. F. Muller,et al.  Specific effect of CV 205-502, a potent nonergot dopamine agonist, during a combined anterior pituitary function test. , 1989, The Journal of clinical endocrinology and metabolism.

[7]  O. Pescovitz,et al.  LACK OF BENEFIT OF CLONIDINE TREATMENT FOR SHORT STATURE IN A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL , 1988, The Lancet.

[8]  A. Grossman,et al.  Acetylcholine and norepinephrine stimulate the release of corticotropin-releasing factor-41 from the rat hypothalamus in vitro. , 1988, Endocrinology.

[9]  J. Tyrrell,et al.  Transsphenoidal microsurgery for Cushing disease. A report of 216 cases. , 1988, Annals of internal medicine.

[10]  P. Hindmarsh,et al.  CONTINUOUS SUBCUTANEOUS GROWTH HORMONE RELEASING FACTOR ANALOGUE AUGMENTS GROWTH HORMONE SECRETION IN NORMAL MALE SUBJECTS WITH NO DESENSITIZATION OF THE SOMATOTROPH , 1988, Clinical Endocrinology.

[11]  A. Grossman,et al.  Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. , 1988, Fertility and sterility.

[12]  N. Ling,et al.  Long term pulsatile growth hormone (GH)-releasing hormone therapy in children with GH deficiency. , 1988, The Journal of clinical endocrinology and metabolism.

[13]  A. Grossman,et al.  A BROMOCRIPTINE‐RESPONSIVE CORTICOTROPH ADENOMA SECRETING α‐MSH IN A PATIENT WITH CUSHING'S DISEASE , 1988, Clinical endocrinology.

[14]  A. Grossman,et al.  GH FEEDBACK OCCURS THROUGH MODULATION OF HYPOTHALAMIC SOMATOSTATIN UNDER CHOLINERGIC CONTROL: STUDIES WITH PYRIDOSTIGMINE AND GHRH , 1987, Clinical endocrinology.

[15]  A. Pontiroli,et al.  Inhibition of basal and metoclopramide-induced prolactin release by cabergoline, an extremely long-acting dopaminergic drug. , 1987, The Journal of clinical endocrinology and metabolism.

[16]  A. Grossman,et al.  The rapid diagnosis of sensitivity or resistance to dopamine agonists with depot bromocriptine. , 1987, Acta endocrinologica.

[17]  M. Vance,et al.  Role of dopamine in the regulation of growth hormone secretion: dopamine and bromocriptine augment growth hormone (GH)-releasing hormone-stimulated GH secretion in normal man. , 1987, The Journal of clinical endocrinology and metabolism.

[18]  P. Bouloux,et al.  Clinical evaluation of lysuride in the management of hyperprolactinaemia. , 1987, British medical journal.

[19]  A. Grossman,et al.  Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man. , 1987, Neuroendocrinology.

[20]  E. Ghigo,et al.  Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia , 1987, Journal of endocrinological investigation.

[21]  M. Preece,et al.  TREATMENT OF GROWTH-HORMONE DEFICIENCY WITH GROWTH-HORMONE-RELEASING HORMONE , 1987, The Lancet.

[22]  A. Grossman,et al.  Alpha 2-adrenoceptor agonists stimulate growth hormone secretion but have no acute effects on plasma cortisol under basal conditions. , 1987, Hormone research.

[23]  E. Ghigo,et al.  Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin. , 1986, The Journal of endocrinology.

[24]  M. Castro-Magana,,et al.  Effect of prolonged clonidine administration on growth hormone concentrations and rate of linear growth in children with constitutional growth delay. , 1986, The Journal of pediatrics.

[25]  R. Caldara,et al.  Long-lasting prolactin-lowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. , 1986, The Journal of clinical endocrinology and metabolism.

[26]  M. Tagliaferri,et al.  Transsphenoidal microsurgery for Cushing's disease. , 1986, Acta endocrinologica.

[27]  A. Grossman,et al.  DEPOT‐BROMOCRIPTINE TREATMENT FOR PROLACTINOMAS AND ACROMEGALY , 1986, Clinical endocrinology.

[28]  H. Kaji,et al.  Augmentation by propranolol of growth hormone-releasing hormone-(1-44)-NH2-induced growth hormone release in normal short and normal children. , 1985, The Journal of clinical endocrinology and metabolism.

[29]  V. Locatelli,et al.  Clonidine accelerates growth in children with impaired growth hormone secretion , 1985, The Lancet.

[30]  A. Grossman,et al.  COMPARISON OF THE CLINICAL ACTIVITY OF MESULERGINE AND PERGOLIDE IN THE TREATMENT OF HYPERPROLACTINAEMIA , 1985, Clinical endocrinology.

[31]  A. Rogol,et al.  Acceleration of growth in two children treated with human growth hormone-releasing factor. , 1985, The New England journal of medicine.

[32]  J. Wass,et al.  Psychotic reactions during treatment of pituitary tumours with dopamine agonists. , 1984, British medical journal.

[33]  H. Koppeschaar,et al.  Sodium valproate and cyproheptadine may independently induce a remission in the same patient with Cushing's disease. , 1983, Acta endocrinologica.

[34]  A. Frantz,et al.  Pergolide for the treatment of pituitary tumors secreting prolactin or growth hormone. , 1983, The New England journal of medicine.

[35]  S. Lamberts,et al.  The evaluation of sodium valproate in the treatment of Nelson's syndrome. , 1983, The Journal of clinical endocrinology and metabolism.

[36]  D. London,et al.  Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia. , 1983, British medical journal.

[37]  W. Vale,et al.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour , 1982, Nature.

[38]  N. Ling,et al.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. , 1982, Science.

[39]  S. Lamberts,et al.  Adrenocorticotropin-secreting pituitary adenomas originate from the anterior or the intermediate lobe in Cushing's disease: differences in the regulation of hormone secretion. , 1982, The Journal of clinical endocrinology and metabolism.

[40]  I. Cobden,et al.  初期食道静脈りゅう治療におけるテルイプレシン(グリプレシン)とバソプレシンの比較試験 , 1982 .

[41]  C. Edwards,et al.  Pregnancy in patients presenting with hyperprolactinaemia. , 1979, British medical journal.

[42]  M. Thorner,et al.  REDUCTION OF PITUITARY-TUMOUR SIZE IN PATIENTS WITH PROLACTINOMAS AND ACROMEGALY TREATED WITH BROMOCRIPTINE WITH OR WITHOUT RADIOTHERAPY , 1979, The Lancet.

[43]  R. Griffith,et al.  Outcome of pregnancy in mothers given bromocriptine. , 1978, British journal of clinical pharmacology.

[44]  Vincent Fm.  Posterior-fossa ependymomas. , 1977 .

[45]  R. Donald,et al.  Cyproheptadine for Cushing's disease (cont.) , 1977, The New England journal of medicine.

[46]  R. Horowski,et al.  Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. , 1976, European journal of pharmacology.

[47]  M. Jones,et al.  Effect on various putative neurotransmitters on the secretion of corticotrophin-releasing hormone from the rat hypothalamus in vitro-a model of the neurotransmitters involved. , 1976, The Journal of endocrinology.

[48]  B. Greenwood.  FAILURE TO DETECT ENDOTOXIN IN SERUM OF CHILDREN WITH MALARIA , 1975, The Lancet.

[49]  C. Edwards,et al.  Galactorrhoea: Successful Treatment with Reduction of Plasma Prolactin Levels by Brom-ergocryptine , 1972, British medical journal.

[50]  A. Frantz,et al.  Prolactin: Evidence That It Is Separate from Growth Hormone in Human Blood , 1970, Science.

[51]  P. Mandel,et al.  EFFECTS OF DI‐n‐PROPYLACETATE, AN ANTICONVULSIVE COMPOUND, ON GABA METABOLISM 1 , 1969, Journal of neurochemistry.

[52]  J. D. Green,et al.  The neurovascular link between the neurohypophysis and adenohypophysis. , 1947, The Journal of endocrinology.